These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24300179)

  • 1. Novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles.
    Kishimoto S; Ishihara M; Takikawa M; Mori Y; Hattori H; Fujita M; Nakamura S
    Pharmaceutics; 2012 Jan; 4(1):42-57. PubMed ID: 24300179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomedical application of low molecular weight heparin/protamine nano/micro particles as cell- and growth factor-carriers and coating matrix.
    Ishihara M; Kishimoto S; Takikawa M; Hattori H; Nakamura S; Shimizu M
    Int J Mol Sci; 2015 May; 16(5):11785-803. PubMed ID: 26006248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier.
    Mori Y; Nakamura S; Kishimoto S; Kawakami M; Suzuki S; Matsui T; Ishihara M
    Int J Nanomedicine; 2010 Apr; 5():147-55. PubMed ID: 20463930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragmin/protamine microparticles as cell carriers to enhance viability of adipose-derived stromal cells and their subsequent effect on in vivo neovascularization.
    Nakamura S; Kishimoto S; Nakamura S; Nambu M; Fujita M; Tanaka Y; Mori Y; Tagawa M; Maehara T; Ishihara M
    J Biomed Mater Res A; 2010 Mar; 92(4):1614-22. PubMed ID: 19437440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragmin/protamine microparticle-coated matrix immobilized cytokines to stimulate various cell proliferations with low serum media.
    Kishimoto S; Nakamura S; Nakamura S; Kanatani Y; Hattori H; Tanaka Y; Harada Y; Tagawa M; Mori Y; Maehara T; Ishihara M
    Artif Organs; 2009 Jun; 33(6):431-8. PubMed ID: 19473138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immobilization, stabilization, and activation of human stem cell factor (SCF) on fragmin/protamine microparticle (F/P MP)-coated plates.
    Kishimoto S; Oonuma F; Nakamura S; Hattori H; Nakamura S; Mori Y; Tanaka Y; Harada Y; Tagawa M; Ishihara M
    J Biomed Mater Res B Appl Biomater; 2010 Jan; 92(1):32-9. PubMed ID: 19637375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of inbred adipose-derived stromal cells in rats with plasma gel containing fragmin/protamine microparticles and FGF-2.
    Sumi Y; Ishihara M; Kishimoto S; Takikawa M; Doumoto T; Azuma R; Nakamura S; Hattori H; Fujita M; Kiyosawa T
    J Biomed Mater Res B Appl Biomater; 2013 Jul; 101(5):784-91. PubMed ID: 23359413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled release of FGF-2 using fragmin/protamine microparticles and effect on neovascularization.
    Nakamura S; Kanatani Y; Kishimoto S; Nakamura S; Ohno C; Horio T; Masanori F; Hattori H; Tanaka Y; Kiyosawa T; Maehara T; Ishihara M
    J Biomed Mater Res A; 2009 Dec; 91(3):814-23. PubMed ID: 19051304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of vascularization and granulation tissue formation by growth factors in human platelet-rich plasma-containing fragmin/protamine microparticles.
    Takikawa M; Nakamura S; Nakamura S; Nambu M; Ishihara M; Fujita M; Kishimoto S; Doumoto T; Yanagibayashi S; Azuma R; Yamamoto N; Kiyosawa T
    J Biomed Mater Res B Appl Biomater; 2011 May; 97(2):373-80. PubMed ID: 21432994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of fragmin/protamine microparticles containing fibroblast growth factor-2 (F/P MPs/FGF-2) to induce collateral vessels in a rabbit model of hindlimb ischemia.
    Horio T; Fujita M; Tanaka Y; Ishihara M; Kishimoto S; Nakamura S; Hase K; Maehara T
    J Vasc Surg; 2011 Sep; 54(3):791-8. PubMed ID: 21620612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragmin/protamine microparticles to adsorb and protect HGF and to function as local HGF carriers in vivo.
    Kishimoto S; Ishihara M; Nakamura S; Fujita M; Takikawa M; Sumi Y; Kiyosawa T; Sato T; Kanatani Y
    Acta Biomater; 2013 Jan; 9(1):4763-70. PubMed ID: 22935325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery system for autologous growth factors fabricated with low-molecular-weight heparin and protamine to attenuate ischemic hind-limb loss in a mouse model.
    Nakamura S; Takikawa M; Ishihara M; Nakayama T; Kishimoto S; Isoda S; Ozeki Y; Sato M; Maehara T
    J Artif Organs; 2012 Dec; 15(4):375-85. PubMed ID: 22890790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion and characterization of human bone marrow-derived mesenchymal stem cells cultured on fragmin/protamine microparticle-coated matrix with fibroblast growth factor-2 in low serum medium.
    Kishimoto S; Hattori H; Nakamura S; Amano Y; Kanatani Y; Tanaka Y; Mori Y; Harada Y; Tagawa M; Ishihara M
    Tissue Eng Part C Methods; 2009 Sep; 15(3):523-7. PubMed ID: 19191666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-carrying polystyrene to mediate cellular attachment and growth via interaction with growth factors.
    Ishihara M; Saito Y; Yura H; Ono K; Ishikawa K; Hattori H; Akaike T; Kurita A
    J Biomed Mater Res; 2000 May; 50(2):144-52. PubMed ID: 10679678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Expansion of CD34+ Cells from Mouse Bone Marrow Cultured on LH/P MP-Coated Plates with Adequate Cytokines.
    Kishimoto S; Ishihara M; Kanatani Y; Nambu M; Takikawa M; Sumi Y; Nakamura S; Mori Y; Hattori H; Tanaka Y; Sato T
    J Tissue Eng; 2011; 2(1):2041731411425419. PubMed ID: 22292106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery system.
    Nakamura S; Ishihara M; Takikawa M; Kishimoto S; Isoda S; Fujita M; Sato M; Maehara T
    Tissue Eng Part A; 2012 Nov; 18(21-22):2239-47. PubMed ID: 22655590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of a biologic graft surface. Effect of treatment with conventional and low molecular weight (LMW) heparin.
    Björck CG; Bergqvist D; Esquivel CO; Larsson R; Rudsvik Y
    Thromb Res; 1984 Sep; 35(6):653-63. PubMed ID: 6506022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective expansion of human adipose-derived stromal cells and bone marrow-derived mesenchymal stem cells cultured on a fragmin/protamine nanoparticles-coated substratum with human platelet-rich plasma.
    Kishimoto S; Ishihara M; Mori Y; Takikawa M; Hattori H; Nakamura S; Sato T
    J Tissue Eng Regen Med; 2013 Dec; 7(12):955-64. PubMed ID: 22473706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.